GB Sciences (GBLX) 10-Q 18 Feb 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Dec. 31, 2019	Feb. 14, 2020
Document Information [Line Items]
Entity Registrant Name	GB SCIENCES INC
Entity Central Index Key	0001165320
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		272,767,352
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 37,300	$ 182,055
Accounts receivable, net of allowance for doubtful accounts of $91,536 and $66,748 at December 31, 2019 and March 31, 2019, respectively	80,436	488,329
Inventory, net	1,560,048	1,533,792
Prepaid expenses and other current assets	83,240	262,208
Note receivable, net of unamortized discount of $884,958 and $0 at December 31, 2019 and March 31, 2019, respectively	1,365,042
Current assets from discontinued operations		1,000,387
TOTAL CURRENT ASSETS	3,126,066	3,466,771
Property and equipment, net	10,097,430	10,481,706
Intangible assets, net of accumulated amortization of $3,745 at December 31, 2019 and March 31, 2019	2,073,839	1,818,802
Note receivable, net of unamortized discount of $383,867 and $0 at December 31, 2019 and March 31, 2019, respectively	5,366,133
Deposits and other noncurrent assets	95,504	230,651
Operating lease right-of-use assets, net	144,146
Non-current assets from discontinued operations		14,025,372
TOTAL ASSETS	20,903,118	30,023,302
CURRENT LIABILITIES:
Accounts payable	1,998,994	1,374,771
Accrued interest	429,064	142,112
Accrued liabilities	469,053	244,931
Notes and convertible notes payable, net of unamortized discount of $1,008,086 and $799,410 at December 31, 2019 and March 31, 2019, respectively	4,860,221	2,229,812
Indebtedness to related parties	324,738
Note payable to related party	151,923
Income tax payable	506,145	506,145
Operating lease obligations, current	47,084
Finance lease obligations, current	134,239	80,132
Current liabilities from discontinued operations		2,134,277
TOTAL CURRENT LIABILITIES	8,921,461	6,712,180
Note payable, net of unamortized discount of $0 and $13,929 at December 31, 2019 and March 31, 2019, respectively		161,072
Operating lease obligations, long term	114,052
Finance lease obligations, long term	3,565,622	3,646,540
Long term liabilities from discontinued operations		2,347,511
TOTAL LIABILITIES	12,601,135	12,867,303
Commitments and contingencies (Note 8)
STOCKHOLDERS' EQUITY:
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 270,553,352 and 240,627,102 shares issued and outstanding at December 31, 2019 and March 31, 2019, respectively	27,056	24,063
Additional paid-in capital	97,039,072	93,020,015
Accumulated deficit	(88,764,145)	(84,743,836)
TOTAL GB SCIENCES, INC. STOCKHOLDERS' EQUITY	8,301,983	8,300,242
Non-controlling interest in discontinued operations		8,855,757
TOTAL EQUITY	8,301,983	17,155,999
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 20,903,118	$ 30,023,302

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 91,536	$ 66,748
Note receivable, unamortized discount, current	884,958	0
Intangible assets, accumulated amortization	3,745	3,745
Note receivable, unamortized discount, noncurrent	383,867	0
Notes and convertible notes payable, unamortized discount, current	1,008,086	799,410
Note payable, unamortized discount, noncurrent	$ 0	$ 13,929
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	270,553,352	240,627,102
Common stock, shares outstanding (in shares)	270,553,352	240,627,102

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Sales revenue	$ 254,131	$ 695,764	$ 2,336,505	$ 2,728,277
Cost of goods sold	(675,933)	(302,569)	(3,157,452)	(1,185,878)
Gross profit (loss)	(421,802)	393,195	(820,947)	1,542,399
General and administrative expenses	1,744,699	2,456,411	5,213,561	10,079,767
LOSS FROM OPERATIONS	(2,166,501)	(2,063,216)	(6,034,508)	(8,537,368)
OTHER INCOME (EXPENSE)
Interest expense, net	(419,264)	(258,522)	(1,332,637)	(4,681,235)
Other expense	(118,695)	(402,504)	74,920	(3,352,311)
Loss on extinguishment	(92,795)		(216,954)
Gain on deconsolidation of subsidiary	4,502,058		4,502,058
Total other income/(expense)	3,871,304	(661,026)	3,027,387	(8,033,546)
NET INCOME/(LOSS) BEFORE INCOME TAXES	1,704,803	(2,724,242)	(3,007,121)	(16,570,914)
Income tax expense		(737,568)		(737,568)
INCOME/(LOSS) FROM CONTINUING OPERATIONS	1,704,803	(3,461,810)	(3,007,121)	(17,308,482)
Loss from discontinued operations	(720,656)	(588,837)	(1,476,220)	(2,124,713)
NET INCOME/(LOSS)	984,147	(4,050,647)	(4,483,341)	(19,433,195)
Net loss attributable to non-controlling interest	(360,327)	(287,406)	(738,107)	(762,966)
NET INCOME/(LOSS) ATTRIBUTABLE TO GB SCIENCES, INC.	1,344,474	(3,763,241)	(3,745,234)	(18,670,229)
Continuing operations	1,704,803	(3,461,810)	(3,007,121)	(17,308,482)
Discontinued operations	(360,329)	(301,431)	(738,113)	(1,361,747)
Net income/(loss)	1,344,474	(3,763,241)	(3,745,234)	(18,670,229)
Continuing operations	1,756,411	(3,461,810)	(3,007,121)	(17,308,482)
Discontinued operations	(360,329)	(301,431)	(738,113)	(1,361,747)
Net income/(loss)	$ 1,396,082	$ (3,763,241)	$ (3,745,234)	$ (18,670,229)
Continuing operations, basic (in dollars per share)	$ 0.01	$ (0.02)	$ (0.01)	$ (0.08)
Discontinued operations, basic (in dollars per share)				(0.01)
Net income/(loss), basic (in dollars per share)	0.01	(0.02)	(0.01)	(0.09)
Continuing operations, diluted (in dollars per share)	0.01	(0.02)	(0.01)	(0.08)
Discontinued operations, diluted (in dollars per share)				(0.01)
Net income/(loss), diluted (in dollars per share)		$ (0.02)	$ (0.01)	$ (0.09)
Weighted average common shares outstanding - basic (in shares)	263,055,254	222,856,453	253,297,660	200,971,724
Weighted average common shares outstanding - diluted (in shares)	325,790,554	222,856,453	253,297,660	200,971,724

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
OPERATING ACTIVITIES:
Net loss	$ (4,483,341)	$ (19,433,195)
Loss from discontinued operations	(1,476,220)	(2,124,713)
Net loss from continuing operations	(3,007,121)	(17,308,482)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	223,249	389,813
Stock-based compensation	588,156	2,322,629
Bad debt expense/(recoveries)	64,522	(18,175)
Amortization of debt discount and beneficial conversion feature	741,912	685,766
Interest expense on conversion of notes payable	93,931	3,464,187
Noncash expense recorded for settlement of royalty agreement (Note 5)		2,140,925
Loss on extinguishment of debt and disposal of assets	224,089	113,623
Loss on induced conversion of note payable	127,059
Gain on deconsolidation of subsidiary	(4,502,058)
Interest income receivable and amortization of discount on note receivable	(170,994)
Changes in operating assets and liabilities:
Accounts receivable	520,565	255,442
Prepaid expenses and other current assets	178,968	1,074,985
Decrease in deposits and other noncurrent assets		131,026
Inventory	343,911	(1,401,906)
Accounts payable	477,913	(155,164)
Accrued expenses	615,667	905,432
Indebtedness to related parties	476,661
Net cash used in operating activities of continuing operations	(3,003,570)	(7,399,899)
Net cash used in operating activities of discontinued operations	(1,244,721)	(447,852)
Net cash used in operating activities	(4,248,291)	(7,847,751)
INVESTING ACTIVITIES:
Purchase of property and equipment	(186,297)	(897,087)
Acquisition of intangible assets	(91,862)	(248,116)
Net cash used in investing activities of continuing operations	(278,159)	(1,145,203)
Net cash used in investing activities of discontinued operations	(260,625)	(8,946,434)
Net cash used in investing activities	(538,784)	(10,091,637)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrant exercises	1,860,200	8,823,555
Proceeds from notes payable and line of credit	2,960,000
Brokerage fees for issuance of common stock and warrants	(175,628)
Fees for issuance of convertible note	(175,000)
Principal payments on debt and finance lease obligations	(110,087)	(318,968)
Cash paid to settle royalty agreement		(1,000,000)
Net cash provided by financing activities of continuing operations	4,359,485	7,504,587
Net cash provided by financing activities of discontinued operations	282,835	7,179,156
Net cash provided by financing activities	4,642,320	14,683,743
Net change in cash and cash equivalents	(144,755)	(3,255,645)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	182,055	3,579,700
CASH AND CASH EQUIVALENTS AT END OF PERIOD	37,300	324,055
Less: cash and cash equivalents classified as discontinued operations		(236,283)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	37,300	87,772
Cash paid for interest	451,040	539,242
Cash paid for income tax
Non-cash transactions:
Stock issued upon conversion of long-term note payable	525,000	4,640,971
Stock issued to settle royalty agreement		131,000
Depreciation capitalized in inventory	370,167	104,481
Induced dividend from warrant exercises	267,525	2,861,436
Property capitalized under operating leases	182,624
Cumulative effect of the new lease standard	7,550
Convertible Notes Payable [Member]
Non-cash transactions:
Beneficial conversion feature on notes payable	$ 829,736

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Mar. 31, 2018	168,616,855
Balance at Mar. 31, 2018	$ 16,862	$ 70,961,104	$ (58,229,235)	$ 2,882,990	$ 15,631,721
Issuance of stock for services (in shares)	3,885,412
Issuance of stock for services	$ 388	1,231,207			1,231,595
Share based compensation expense (in shares)
Share based compensation expense		831,729			831,729
Issuance of stock for cash, net of issuance costs (in shares)	23,747,778
Issuance of stock for cash, net of issuance costs	$ 2,375	4,900,460			4,902,835
Contributions from non-controlling interest				6,920,856	6,920,856
Shares common stock issued to Pacific Leaf (in shares)	600,000
Stock issued to settle royalty agreement	$ 60	130,940			131,000
Net Income/(Loss)			(18,670,229)	(762,966)	(19,433,195)
Issuance of stock for debt conversion (in shares)	18,563,885
Issuance of stock for debt conversion	$ 1,856	4,639,115			4,640,971
Exercise of warrants for stock (in shares)	12,657,875
Exercise of warrants for stock	$ 1,266	3,919,454			3,920,720
Inducement dividend from warrant exercises		2,861,436	(2,861,436)
Compensation warrants		592,638			592,638
Balance (in shares) at Dec. 31, 2018	228,071,805
Balance at Dec. 31, 2018	$ 22,807	90,068,083	(79,760,900)	9,040,880	19,370,870
Balance (in shares) at Sep. 30, 2018	221,760,237
Balance at Sep. 30, 2018	$ 22,176	88,860,249	(75,997,660)	9,122,287	22,007,052
Issuance of stock for services (in shares)	2,341,568
Issuance of stock for services	$ 234	489,671			489,905
Share based compensation expense (in shares)
Share based compensation expense		170,725			170,725
Issuance of stock for cash, net of issuance costs (in shares)	3,470,000
Issuance of stock for cash, net of issuance costs	$ 347	452,488			452,835
Contributions from non-controlling interest				206,000	206,000
Shares common stock issued to Pacific Leaf (in shares)	500,000
Stock issued to settle royalty agreement	$ 50	94,950			95,000
Net Income/(Loss)			(3,763,240)	(287,407)	(4,050,647)
Balance (in shares) at Dec. 31, 2018	228,071,805
Balance at Dec. 31, 2018	$ 22,807	90,068,083	(79,760,900)	9,040,880	19,370,870
Balance (in shares) at Mar. 31, 2019	240,627,102
Balance at Mar. 31, 2019	$ 24,063	93,020,015	(84,743,836)	8,855,757	$ 17,155,999
Issuance of stock for services (in shares)	2,500,000				2,500,000
Issuance of stock for services	$ 250	213,750			$ 214,000
Share based compensation expense (in shares)
Share based compensation expense		241,242			$ 241,242
Issuance of stock for cash, net of issuance costs (in shares)	7,668,167				7,668,167
Issuance of stock for cash, net of issuance costs	$ 768	717,929			$ 718,697
Contributions from non-controlling interest				590,000	590,000
Stock issued to settle royalty agreement
Net Income/(Loss)			(3,745,234)	(738,107)	(4,483,341)
Issuance of stock for debt conversion (in shares)	7,583,333
Issuance of stock for debt conversion	$ 758	524,242			$ 525,000
Exercise of warrants for stock (in shares)	12,574,750				12,574,750
Exercise of warrants for stock	$ 1,257	964,620			$ 965,877
Beneficial conversion feature on notes payable		829,736			829,736
Inducement dividend from warrant exercises		267,525	(267,525)
Induced note conversions		127,059			127,059
Deconsolidation of subsidiary				(8,707,650)	(8,707,650)
Compensation warrants		132,914			132,914
Cancellation of shares issued to consultant (in shares)	(400,000)
Cancellation of shares issued to consultant	$ (40)	40
Cumulative effect of the new lease standard			(7,550)		(7,550)
Balance (in shares) at Dec. 31, 2019	270,553,352
Balance at Dec. 31, 2019	$ 27,056	97,039,072	(88,764,145)		8,301,983
Balance (in shares) at Sep. 30, 2019	255,345,019
Balance at Sep. 30, 2019	$ 25,535	95,333,271	(90,071,120)	9,027,977	14,315,663
Issuance of stock for services (in shares)	2,500,000
Issuance of stock for services	$ 250	213,750			214,000
Share based compensation expense (in shares)
Share based compensation expense		32,431			32,431
Issuance of stock for cash, net of issuance costs (in shares)	4,000,000
Issuance of stock for cash, net of issuance costs	$ 400	239,600			240,000
Contributions from non-controlling interest				40,000	40,000
Net Income/(Loss)			1,344,474	(360,327)	984,147
Issuance of stock for debt conversion (in shares)	5,583,333
Issuance of stock for debt conversion	$ 558	244,442			245,000
Exercise of warrants for stock (in shares)	3,125,000
Exercise of warrants for stock	$ 313	115,088			115,401
Beneficial conversion feature on notes payable		695,932			695,932
Inducement dividend from warrant exercises		37,499	(37,499)
Induced note conversions		127,059			127,059
Deconsolidation of subsidiary				(8,707,650)	(8,707,650)
Balance (in shares) at Dec. 31, 2019	270,553,352
Balance at Dec. 31, 2019	$ 27,056	$ 97,039,072	$ (88,764,145)		$ 8,301,983

Note 1 - Background and Signifi

Note 1 - Background and Significant Accounting Policies	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1 GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) seeks to be a biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. The Company is is engaged in the research and development of cannabinoid medicines and plans to produce cannabinoid therapies for the wellness markets based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of cannabinoid medicines with virtual operations in North America and Europe. GBSGB assets include cannabinoid medicine intellectual property, research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of conditions and several programs are in pre-clinical animal stage of development; including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes four four three March 31, 2020, three We currently hold 100% November 15, 2019, 75% $3 $3 We recently completed the sale of the Company's controlling interest in GB Sciences Louisiana, LLC, which has partnered with Louisiana State University to operate a cultivation and extraction facility to produce products for the medical cannabis market. As consideration for the sale of our controlling membership interest in GB Sciences Louisiana, LLC, we received an $8 may $8 50% Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2020. March 31, 2019 not 10 March 31, 2019 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. The current and long-term capital lease obligations recorded in the consolidated balance sheet as of March 31, 2019 10 no Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets are as follows: Discontinued Operations – (continued) December 31, 2019 March 31, 2019 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 37,300 $ - $ 37,300 $ 182,055 $ 45,703 $ 227,758 Accounts receivable, net 80,436 - 80,436 488,329 - 488,329 Inventory, net 1,560,048 - 1,560,048 1,533,792 602,714 2,136,506 Prepaid and other current assets 83,240 - 83,240 262,208 351,970 614,178 Note receivable 1,365,042 - 1,365,042 - - - TOTAL CURRENT ASSETS 3,126,066 - 3,126,066 2,466,384 1,000,387 3,466,771 Property and equipment, net 10,097,430 - 10,097,430 10,481,706 13,022,996 23,504,702 Intangible assets, net 2,073,839 - 2,073,839 1,818,802 - 1,818,802 Note receivable 5,366,133 - 5,366,133 - - - Deposits and other noncurrent assets 95,504 - 95,504 230,651 1,002,376 1,233,027 Operating lease right-of-use assets, net 144,146 - 144,146 - - - TOTAL ASSETS $ 20,903,118 $ - $ 20,903,118 $ 14,997,543 $ 15,025,759 $ 30,023,302 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,998,994 $ - $ 1,998,994 $ 1,374,771 $ 1,695,985 $ 3,070,756 Accrued interest 429,064 - 429,064 142,112 - 142,112 Accrued expenses 469,053 - 469,053 244,931 76,415 321,346 Notes payable, net 4,860,221 - 4,860,221 2,229,812 300,000 2,529,812 Indebtedness to related parties 476,661 - 476,661 - - - Income tax payable 506,145 - 506,145 506,145 - 506,145 Operating lease obligations, current 47,084 - 47,084 - - - Finance lease obligations, current 134,239 - 134,239 80,132 61,877 142,009 TOTAL CURRENT LIABILITIES 8,921,461 - 8,921,461 4,577,903 2,134,277 6,712,180 Note payable, net - - - 161,072 161,072 Operating lease obligations, long term 114,052 - 114,052 - - Finance lease obligations, long term 3,565,622 - 3,565,622 3,646,540 2,347,511 5,994,051 TOTAL LIABILITIES $ 12,601,135 $ - $ 12,601,135 $ 8,385,515 $ 4,481,788 $ 12,867,303 The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations were as follows: For the Three Months Ended December 31, 2019 2018 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 254,131 $ 192,070 $ 446,201 $ 695,764 $ - $ 695,764 Cost of goods sold (675,933 ) (193,915 ) (869,848 ) (302,569 ) - (302,569 ) Gross profit (loss) (421,802 ) (1,845 ) (423,647 ) 393,195 - 393,195 General and administrative expenses 1,744,699 666,042 2,410,741 2,456,411 526,210 2,982,621 LOSS FROM OPERATIONS (2,166,501 ) (667,887 ) (2,834,388 ) (2,063,216 ) (526,210 ) (2,589,426 ) OTHER INCOME/(EXPENSE) Interest expense (419,264 ) (52,769 ) (472,033 ) (258,522 ) (62,627 ) (321,149 ) Other income/(expense) (118,695 ) - (118,695 ) (402,504 ) (402,504 ) Loss on extinguishment (92,795 ) - (92,795 ) - - - Gain on deconsolidation of subsidiary 4,502,058 - 4,502,058 - - - Total other expense 3,871,304 (52,769 ) 3,818,535 (661,026 ) (62,627 ) (723,653 ) NET LOSS BEFORE INCOME TAXES 1,704,803 (720,656 ) 984,147 (2,724,242 ) (588,837 ) (3,313,079 ) Income tax expense - - - (737,568 ) - (737,568 ) NET INCOME/(LOSS) $ 1,704,803 $ (720,656 ) $ 984,147 $ (3,461,810 ) $ (588,837 ) $ (4,050,647 ) For the Nine Months Ended December 31, 2019 2018 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 2,336,505 $ 569,077 $ 2,905,582 $ 2,728,277 $ - $ 2,728,277 Cost of goods sold (3,157,452 ) (574,544 ) (3,731,996 ) (1,185,878 ) - (1,185,878 ) Gross profit (loss) (820,947 ) (5,467 ) (826,414 ) 1,542,399 - 1,542,399 General and administrative expenses 5,213,561 1,292,613 6,506,174 10,079,767 1,935,766 12,015,533 LOSS FROM OPERATIONS (6,034,508 ) (1,298,080 ) (7,332,588 ) (8,537,368 ) (1,935,766 ) (10,473,134 ) OTHER INCOME/(EXPENSE) Interest expense (1,332,637 ) (178,140 ) (1,510,777 ) (4,681,235 ) (188,947 ) (4,870,182 ) Other income/(expense) 74,920 - 74,920 (3,352,311 ) - (3,352,311 ) Loss on extinguishment (216,954 ) - (216,954 ) - - - Gain on deconsolidation of subsidiary 4,502,058 - 4,502,058 - - - Total other expense 3,027,387 (178,140 ) 2,849,247 (8,033,546 ) (188,947 ) (8,222,493 ) NET LOSS BEFORE INCOME TAXES (3,007,121 ) (1,476,220 ) (4,483,341 ) (16,570,914 ) (2,124,713 ) (18,695,627 ) Income tax expense - - - (737,568 ) - (737,568 ) NET LOSS $ (3,007,121 ) $ (1,476,220 ) $ (4,483,341 ) $ (17,308,482 ) $ (2,124,713 ) $ (19,433,195 ) Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not No March 31, 2019 Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not Earnings/(loss) per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 158,728,095 108,999,521 December 31, 2019 2018 nine December 31, 2019 three nine December 31, 2018, not three December 31, 2019, For the Three Months Ended December 31, 2019 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 1,704,803 Plus: Income impact of assumed conversions Interest expense on convertible notes payable 51,608 Effect of assumed conversions 51,608 Income from continuing operations plus assumed conversions 1,756,411 Net loss from discontinued operations available to common stockholders (360,329 ) Net income available to common stockholders $ 1,396,082 Weighted-average common shares outstanding 263,055,254 Plus: incremental shares from assumed conversions Warrants 26,648,530 Convertible notes payable 36,086,770 Dilutive potential common shares 62,735,300 Adjusted weighted-average shares 325,790,554 Diluted EPS Net income from continuing operations $ 1,756,411 325,790,554 $ 0.01 Net loss from discontinued operations $ (360,329 ) 325,790,554 $ (0.00 ) Net loss $ 1,396,082 325,790,554 $ 0.00 Recent Accounting Pronouncements Recently Adopted Standards In February 2016, 2016 02, 842 Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the standard. Lease payments do not December 15, 2018 April 1, 2019. not The Company adopted the New Lease Standard using the modified retrospective transition approach as of the effective date as permitted by the amendments in ASU 2018 11, 842 not April 1, 2019. The Company's consolidated balance sheet was affected by this standard, but the consolidated statement of operations and consolidated statement of cash flows were not April 1, 2019 $182,624, $190,173 In June 2018, 2018 07, 718 2018 07” No 2018 07 718 718 December 15, 2018, April 1, 2019. no All other newly issued accounting pronouncements but not not

Note 2 - Going Concern

Note 2 - Going Concern	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $ ( 88,764,145 December 31, 2019 $ ( 5,795,395 December 31, 2019 $ ( 3,245,409 $ ( 1,133,890 March 31, 2019 ( 4,248,291 ( 1,244,721 nine December 31, 2019 ( 7,847,751 ( 447,852 Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not may

Note 3 - Inventory

Note 3 - Inventory	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 3 Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, extracts, and vapes in bulk and packaged forms. December 31, 2019 March 31, 2019 Raw materials $ 299,740 $ 440,414 Work in progress 1,495,301 676,341 Finished goods 257,995 579,604 Allowance to reduce inventory to NRV (492,988 ) (162,567 ) Total inventory $ 1,560,048 $ 1,533,792

Note 4 - Leases

Note 4 - Leases	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Lessee, Operating and Finance Leases [Text Block]	Note 4 The Company determines if an arrangement is a lease at inception and has lease agreements for warehouses, office facilities, and equipment. These commitments have remaining non-cancelable lease terms, with lease expirations which range from 2021 2032. As a result of the adoption of ASC 842, $182,624, $190,173 April 1, 2019, Operating leases are included in other current assets , accrued liabilities, and operating lease obligations, long term on the unaudited condensed consolidated balance sheets. Finance leases are included in property and equipment, finance lease obligations, short term, and finance lease obligations, long term, on the unaudited condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% 11.5%. 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not During the nine December 31, 2019 $ 790,666 $ 474,686 $ 315,980 $ 61,144 $ 22,667 $ 38,477 Discontinued operations includes $ 280,227 $ 153,977 $ 126,250 Amortization of lease assets is included in general and administrative expenses. The future minimum lease payments of lease liabilities as of December 31, 2019 Year Ending Operating March 31, Finance Leases Leases 2020 (3 months) $ 185,871 $ 17,547 2021 528,443 71,548 2022 544,296 73,939 2023 560,625 38,101 2024 577,444 3,926 Thereafter 4,375,869 - Total undiscounted lease payments 6,772,548 205,061 Less: Amount representing interest (3,072,687 ) (43,925 ) Present value of minimum lease payments 3,699,861 161,136 Less: Current maturities of lease obligations (134,239 ) (47,084 ) Long-term lease obligations $ 3,565,622 $ 114,052

Note 5 - Notes Payable

Note 5 - Notes Payable	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 6% November 30, 2018 On July 28, 2018, $1 $1.5 August 31, 2018. $0.5 6% November 30, 2018. $5,425 three December 31, 2018 In consideration for deferring the payment of the amounts due to Pacific Leaf, the Company issued 100,000 July 31, 2018 $36,000. $1.0 August 2018 $36,000 $ 1,000,000 August 2018 September 31, 2018, On December 21, 2018, $100,000 $12,164 $87,836 On December 21, 2018, 500,000 95,000 March 31, 2019 The Company made additional payments on the promissory note of $100,000 January 16, 2019, $100,000 February 6, 2019, $210,000 March 4, 2019 Because the Amendment and Termination Agreement irrevocably terminated the Pacific Leaf Royalty Agreement Royalty Agreement, the Company recorded an expense of $1,530,000 December 31, 2018 February 2018 nine December 31, 2018 $3.1 nine December 31, 2018 Amounts Recorded in Other Expense Related to Royalty Settlement For the Nine Months Ended December 31, 2018 Prepaid royalties expensed during the quarter $ 1,530,000 Promissory note issued to Pacific Leaf, due on or before November 30, 2018 500,000 600,000 shares common stock issued to Pacific Leaf 131,000 Long-term note payable and accrued interest terminated (20,075 ) Total non-cash expense 2,140,925 Cash payments made in August 2018 1,000,000 Total $ 3,140,925 0% October 23, 2017 On October 23, 2017, 100% 100% one $500,000 0% $700,000 three January 1, 2018. The present value of the note was $521,067 20.3% $178,933. nine December 31, 2019 $31,092 The Company has been in default on this note since June 2019, eight $155,555 ten 483 $369,444 10%, Line of Credit dated November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019, $470,000 75% nine December 31, 2019 $330,000 December 31, 2019 $150,000 $480,000 $10,000. December 31, 2019 $330,000. Note payable to BCM MED, LLC On December 20, 2018, $300,000 Pursuant to the Loan Agreement, GBSLA began making eight 8 $33,333 10 th April 2019. November 15, 2019, $266,667 $33,333. 10 Summary of Notes Payable and Convertible Notes As of December 31, 2019 As of December 31, 2019 Short-Term Notes Payable Face Value Discount Carrying Value 6% Convertible promissory notes payable (Note 6) $ 1,257,000 $ (257,177 ) $ 999,823 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (584,842 ) 687,021 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,640,000 (142,314 ) 2,497,686 0% Note Payable dated October 23, 2017, current portion 369,444 (23,753 ) 345,691 Line of Credit dated November 27, 2019 330,000 - 330,000 Note Payable to John Davis (Note 9) 151,923 - 151,923 Total Short-Term Notes Payable $ 6,020,230 $ (1,008,086 ) $ 5,012,144

Note 6 - Convertible Notes

Note 6 - Convertible Notes	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Convertible Debt [Text Block]	Note 6 March 2017 In March 2017, $965,500. three 3,862,000 3,862,000 one $0.60 three $416,733 $548,767 During the three June 30, 2017, $1,034,500. three 4,138,000 4,138,000 one $0.60 three $487,957 $480,236 July 2017 In July 2017, third $1,000 6% 4,000 $0.25 4,000 $0.65 three During the three September 30, 2017, $3,085,000. three 12,340,000 12,340,000 one $0.65 three $1,541,797 $1,532,335 During the three December 31, 2017, $4,116,000. three 16,464,000 16,464,000 one $0.65 three $1,600,808 $2,417,856 As of December 31, 2019 $ 999,823 $ ( 257,177 March 2017 July 2017 $ 178,381 nine December 31, 2019 $ 364,575 $ 307,752 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, $1,500,000 8% August 28, 2020 8,823,529 $0.17 100% The intrinsic value of the beneficial conversion feature resulting from the market price of the Company’s common stock in excess of the conversion price was $176,471 nine December 31, 2019 $32,186 $61,286 On May 28, 2019, $170,000 8% February 28, 2019. 1,000,000 $0.17 17,225 $152,775. $1,330,000. On July 12, 2019, 8% $100,000 $100,000 July 12, 2019, $41,863 $0.11 We evaluated the modification under the guidance in ASC 470 50 10% $1,338,057, $133,806, $124,158. On August 1, 2019, 110,000 $0.11 1,000,000 $9,579 $100,421. 1,361,863. On October 23, 2019, October 23, 2019 $0.08 We evaluated the modification under the guidance in ASC 470 50 10% 2nd $1,269,067, $92,796, $92,796. On November 27, 2019, 8% “2nd 2nd $0.04 $30,000 We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd no 2nd $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 During the nine December 31, 2019 $ 89,624 $ 27,270 $ 62,354 The Company is in default on the amended CSW Note due to non-payment of the quarterly interest payments due on October 1, 2019, January 1, 2020, March 31, 2018 5 ten not 75% 10 may 10%, 8% April 23, 2019 On April 23, 2019, 8% $2,765,000. $265,000 $0.17 April 22, 2020. A total discount of $440,000 $265,000 $175,000 nine December 31, 2019 $ 164,150 $ 109,870 The Company may March 31, 2018 may 5 6. not 15% 10%. As inducement for the temporary forbearance of formal default proceedings, the Company has honored the conversion of a total of a total of $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 $62,353, $ 127,059 two three nine December 31, 2019

Note 7 - Capital Transactions

Note 7 - Capital Transactions	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 7 Increase in Authorized Capital Effective April 8, 2018, 250,000,000 400,000,000. August 15, 2019, 400,000,000 600,000,000. Sale of Common Stock and Exercise of Warrants Stock Issued for Debt Conversions During the nine December 31, 2019 7,583,333 On May 28, 2019, $170,000 8% February 28, 2019 ( 6 1,000,000 $0.17 $17,225 $152,775. On August 1, 2019, $110,000 $0.11 1,000,000 $9,579 $100,421. $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 As inducement for the temporary forbearance of formal default proceedings, the Company has honored the conversion of a total of a total of $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 $62,353, $ 127,059 two three nine December 31, 2019 Exercise of Warrants for Stock During the nine December 31, 2019 12,574,750 In order to encourage the exercise of approximately 70.5 $0.65 $0.30, $0.10 July 11, 2019. July 12, 2019, August 30, 2019, July 31, 2019, December 31, 2019 9,449,750 $850,478, $94,498. $230,025. In order to encourage the further exercise of the same warrants, the Company effected a temporary decrease in the exercise price of the warrants to $0.04 December 2019. 3,125,000 $112,500, $12,500. 37,499 Issuance of Stock for Services During the nine December 31, 2019 2,500,000 $214,000 Issuance of Stock for Cash During the nine December 31, 2019 7,668,167 On December 4, 2018, 15,000,000 $0.20 $3 one one one $0.60 five January 15, 2019, $0.20 $0.15 20,000,000 $0.60 $0.30, no nine December 31, 2019 $478,696 $71,529 3,668,167 3,668,167 one $0.30 On October 10, 2019, 4,000,000 2,000,000 one $0.08 three $240,000 $110,000 Cancellation of Shares Issued to Consultant During the nine December 31, 2019 400,000 March 31, 2019 June 30, 2019, not December 31, 2019 Options and Warrants At the conclusion of the December 2018 December 31, 2019 1,954,613 $0.30 June 15, 2024 132,914 As of December 31, 2019, 87,526,411 $0.30 $1.00 For the nine December 31, 2019 241,242 December 31, 2019, $15,131 December 31, 2019, 10,383,334 2,383,000

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8 On September 18, 2017 five two five The contract includes the Company’s commitment to make an annual research investments of $500,000 50% 10 $250,000 $500,000 three $750,000. September one The monetary contributions will be used to conduct research on plant varieties, compounds, extraction techniques and delivery methods that could generate additional revenue through discoveries that are subject to intellectual property rights, of which AgCenter would retain 50% 50% 25% On December 6, 2018, 2 $0.1125 $244,000 $162,667 nine December 31, 2019 $10,000 12 4 2 2 nine On June 6, 2019, December 6, 2018 $135,000 one not two million December 31, 2019 On October 1, 2019, 2 $50,000 December 1, 2019, 2 90, 180, 270 $180,000 $50,000 December 31, 2019 During the year ended March 31, 2019 $200,000 one not not September 6, 2019, From time to time, the Company may not

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 9 As of December 31, 2019 $324,738, $142,637 $75,747 $106,354 In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 first 10 During the fiscal year ended March 31, 2017, one nine December 31, 2018, $1.1 During the year ended March 31, 2017, one one March 31, 2018. nine December 31, 2018, $73,904 285,412 $99,596. December 31, 2018, On November 1, 2017, 20% 25% Contemporaneously with the EPA, the Company entered into a Non-Revolving Credit Line Agreement and Non-Revolving Credit Line Promissory Note (together, the “THC Note” or “Note”) to advance up to $300,000 90 first 25% As of December 31, 2018, $253,034 October 19, 2018 October 22, 2018, The Company assessed the fair value of the machinery and equipment received at $139,411 December 31, 2018. $ 113,623 three nine December 31, 2018,

Note 10 - Sale of 50% Membershi

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC	9 Months Ended
	Dec. 31, 2019
GB Sciences Louisiana, LLC, Sale of Equity [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 10 50% On February 12, 2018, 15% $3 35% 5% $1 $7.0 49.99%. On November 15, 2019, 50.01% $8,000,000 may $8,000,000 The Wellcana note bears interest at a rate of 5% June 1, 2020, December 1, 2021. $1,389,408 17.0%, $6,610,592 November 15, 2019: Wellcana Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 TOTAL PAYMENTS 8,000,000 DISCOUNT ON NOTE RECEIVABLE (1,389,408 ) NET PRESENT VALUE $ 6,610,592 The Company may $8,000,000 25% September 30, 2022, 10% 1 2 no Based on the foregoing assessment of the consideration received, the Company recorded a gain on deconsolidation of $4,502,058 As of November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 TOTAL 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,899,613 ) Net assets deconsolidated 10,816,185 GAIN ON DECONSOLIDATION $ 4,502,058 For all periods presented in the unaudited financial statements, the assets, liabilities, income, and cash flows of GBSLA have been reclassified to discontinued operations. The losses and cash flows from discontinued operations for the three nine December 31, 2019 November 15, 2019.

Note 11 - Sale of Membership In

Note 11 - Sale of Membership Interests in Nevada Subsidiaries	9 Months Ended
	Dec. 31, 2019
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 11 The Company operates cannabis cultivation and extraction facilities located at 3550 89118. two On November 27, 2019, 75% $3,000,000 $3,000,000 may In connection with the Teco LOI, on December 6, 2019, $75,000 no In connection with the Teco LOI, the Company also entered into a Line of Credit of up to $470,000 5 8% 6 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company’s wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, 100% $300,000.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12 Capital Transactions Subsequent to December 31, 2019 2,214,000 $0.04 7 $79,704, $8,856.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2020. March 31, 2019 not 10 March 31, 2019
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. The current and long-term capital lease obligations recorded in the consolidated balance sheet as of March 31, 2019 10 no
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The assets and liabilities associated with discontinued operations included in our condensed consolidated balance sheets are as follows: December 31, 2019 March 31, 2019 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 37,300 $ - $ 37,300 $ 182,055 $ 45,703 $ 227,758 Accounts receivable, net 80,436 - 80,436 488,329 - 488,329 Inventory, net 1,560,048 - 1,560,048 1,533,792 602,714 2,136,506 Prepaid and other current assets 83,240 - 83,240 262,208 351,970 614,178 Note receivable 1,365,042 - 1,365,042 - - - TOTAL CURRENT ASSETS 3,126,066 - 3,126,066 2,466,384 1,000,387 3,466,771 Property and equipment, net 10,097,430 - 10,097,430 10,481,706 13,022,996 23,504,702 Intangible assets, net 2,073,839 - 2,073,839 1,818,802 - 1,818,802 Note receivable 5,366,133 - 5,366,133 - - - Deposits and other noncurrent assets 95,504 - 95,504 230,651 1,002,376 1,233,027 Operating lease right-of-use assets, net 144,146 - 144,146 - - - TOTAL ASSETS $ 20,903,118 $ - $ 20,903,118 $ 14,997,543 $ 15,025,759 $ 30,023,302 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,998,994 $ - $ 1,998,994 $ 1,374,771 $ 1,695,985 $ 3,070,756 Accrued interest 429,064 - 429,064 142,112 - 142,112 Accrued expenses 469,053 - 469,053 244,931 76,415 321,346 Notes payable, net 4,860,221 - 4,860,221 2,229,812 300,000 2,529,812 Indebtedness to related parties 476,661 - 476,661 - - - Income tax payable 506,145 - 506,145 506,145 - 506,145 Operating lease obligations, current 47,084 - 47,084 - - - Finance lease obligations, current 134,239 - 134,239 80,132 61,877 142,009 TOTAL CURRENT LIABILITIES 8,921,461 - 8,921,461 4,577,903 2,134,277 6,712,180 Note payable, net - - - 161,072 161,072 Operating lease obligations, long term 114,052 - 114,052 - - Finance lease obligations, long term 3,565,622 - 3,565,622 3,646,540 2,347,511 5,994,051 TOTAL LIABILITIES $ 12,601,135 $ - $ 12,601,135 $ 8,385,515 $ 4,481,788 $ 12,867,303 The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations were as follows: For the Three Months Ended December 31, 2019 2018 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 254,131 $ 192,070 $ 446,201 $ 695,764 $ - $ 695,764 Cost of goods sold (675,933 ) (193,915 ) (869,848 ) (302,569 ) - (302,569 ) Gross profit (loss) (421,802 ) (1,845 ) (423,647 ) 393,195 - 393,195 General and administrative expenses 1,744,699 666,042 2,410,741 2,456,411 526,210 2,982,621 LOSS FROM OPERATIONS (2,166,501 ) (667,887 ) (2,834,388 ) (2,063,216 ) (526,210 ) (2,589,426 ) OTHER INCOME/(EXPENSE) Interest expense (419,264 ) (52,769 ) (472,033 ) (258,522 ) (62,627 ) (321,149 ) Other income/(expense) (118,695 ) - (118,695 ) (402,504 ) (402,504 ) Loss on extinguishment (92,795 ) - (92,795 ) - - - Gain on deconsolidation of subsidiary 4,502,058 - 4,502,058 - - - Total other expense 3,871,304 (52,769 ) 3,818,535 (661,026 ) (62,627 ) (723,653 ) NET LOSS BEFORE INCOME TAXES 1,704,803 (720,656 ) 984,147 (2,724,242 ) (588,837 ) (3,313,079 ) Income tax expense - - - (737,568 ) - (737,568 ) NET LOSS $ 1,704,803 $ (720,656 ) $ 984,147 $ (3,461,810 ) $ (588,837 ) $ (4,050,647 ) For the Nine Months Ended December 31, 2019 2018 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 2,336,505 $ 569,077 $ 2,905,582 $ 2,728,277 $ - $ 2,728,277 Cost of goods sold (3,157,452 ) (574,544 ) (3,731,996 ) (1,185,878 ) - (1,185,878 ) Gross profit (loss) (820,947 ) (5,467 ) (826,414 ) 1,542,399 - 1,542,399 General and administrative expenses 5,213,561 1,292,613 6,506,174 10,079,767 1,935,766 12,015,533 LOSS FROM OPERATIONS (6,034,508 ) (1,298,080 ) (7,332,588 ) (8,537,368 ) (1,935,766 ) (10,473,134 ) OTHER INCOME/(EXPENSE) Interest expense (1,332,637 ) (178,140 ) (1,510,777 ) (4,681,235 ) (188,947 ) (4,870,182 ) Other income/(expense) 74,920 - 74,920 (3,352,311 ) - (3,352,311 ) Loss on extinguishment (216,954 ) - (216,954 ) - - - Gain on deconsolidation of subsidiary 4,502,058 - 4,502,058 - - - Total other expense 3,027,387 (178,140 ) 2,849,247 (8,033,546 ) (188,947 ) (8,222,493 ) NET LOSS BEFORE INCOME TAXES (3,007,121 ) (1,476,220 ) (4,483,341 ) (16,570,914 ) (2,124,713 ) (18,695,627 ) Income tax expense - - - (737,568 ) - (737,568 ) NET LOSS $ (3,007,121 ) $ (1,476,220 ) $ (4,483,341 ) $ (17,308,482 ) $ (2,124,713 ) $ (19,433,195 )
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not No March 31, 2019
Inventory, Policy [Policy Text Block]	Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not
Earnings Per Share, Policy [Policy Text Block]	Earnings/(loss) per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 158,728,095 108,999,521 December 31, 2019 2018 nine December 31, 2019 three nine December 31, 2018, not three December 31, 2019, For the Three Months Ended December 31, 2019 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 1,704,803 Plus: Income impact of assumed conversions Interest expense on convertible notes payable 51,608 Effect of assumed conversions 51,608 Income from continuing operations plus assumed conversions 1,756,411 Net loss from discontinued operations available to common stockholders (360,329 ) Net income available to common stockholders $ 1,396,082 Weighted-average common shares outstanding 263,055,254 Plus: incremental shares from assumed conversions Warrants 26,648,530 Convertible notes payable 36,086,770 Dilutive potential common shares 62,735,300 Adjusted weighted-average shares 325,790,554 Diluted EPS Net income from continuing operations $ 1,756,411 325,790,554 $ 0.01 Net loss from discontinued operations $ (360,329 ) 325,790,554 $ (0.00 ) Net loss $ 1,396,082 325,790,554 $ 0.00
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recently Adopted Standards In February 2016, 2016 02, 842 Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the standard. Lease payments do not December 15, 2018 April 1, 2019. not The Company adopted the New Lease Standard using the modified retrospective transition approach as of the effective date as permitted by the amendments in ASU 2018 11, 842 not April 1, 2019. The Company's consolidated balance sheet was affected by this standard, but the consolidated statement of operations and consolidated statement of cash flows were not April 1, 2019 $182,624, $190,173 In June 2018, 2018 07, 718 2018 07” No 2018 07 718 718 December 15, 2018, April 1, 2019. no All other newly issued accounting pronouncements but not not

Note 1 - Background and Signi_2

Note 1 - Background and Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2019
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	Discontinued Operations – (continued) December 31, 2019 March 31, 2019 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 37,300 $ - $ 37,300 $ 182,055 $ 45,703 $ 227,758 Accounts receivable, net 80,436 - 80,436 488,329 - 488,329 Inventory, net 1,560,048 - 1,560,048 1,533,792 602,714 2,136,506 Prepaid and other current assets 83,240 - 83,240 262,208 351,970 614,178 Note receivable 1,365,042 - 1,365,042 - - - TOTAL CURRENT ASSETS 3,126,066 - 3,126,066 2,466,384 1,000,387 3,466,771 Property and equipment, net 10,097,430 - 10,097,430 10,481,706 13,022,996 23,504,702 Intangible assets, net 2,073,839 - 2,073,839 1,818,802 - 1,818,802 Note receivable 5,366,133 - 5,366,133 - - - Deposits and other noncurrent assets 95,504 - 95,504 230,651 1,002,376 1,233,027 Operating lease right-of-use assets, net 144,146 - 144,146 - - - TOTAL ASSETS $ 20,903,118 $ - $ 20,903,118 $ 14,997,543 $ 15,025,759 $ 30,023,302 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,998,994 $ - $ 1,998,994 $ 1,374,771 $ 1,695,985 $ 3,070,756 Accrued interest 429,064 - 429,064 142,112 - 142,112 Accrued expenses 469,053 - 469,053 244,931 76,415 321,346 Notes payable, net 4,860,221 - 4,860,221 2,229,812 300,000 2,529,812 Indebtedness to related parties 476,661 - 476,661 - - - Income tax payable 506,145 - 506,145 506,145 - 506,145 Operating lease obligations, current 47,084 - 47,084 - - - Finance lease obligations, current 134,239 - 134,239 80,132 61,877 142,009 TOTAL CURRENT LIABILITIES 8,921,461 - 8,921,461 4,577,903 2,134,277 6,712,180 Note payable, net - - - 161,072 161,072 Operating lease obligations, long term 114,052 - 114,052 - - Finance lease obligations, long term 3,565,622 - 3,565,622 3,646,540 2,347,511 5,994,051 TOTAL LIABILITIES $ 12,601,135 $ - $ 12,601,135 $ 8,385,515 $ 4,481,788 $ 12,867,303 For the Three Months Ended December 31, 2019 2018 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 254,131 $ 192,070 $ 446,201 $ 695,764 $ - $ 695,764 Cost of goods sold (675,933 ) (193,915 ) (869,848 ) (302,569 ) - (302,569 ) Gross profit (loss) (421,802 ) (1,845 ) (423,647 ) 393,195 - 393,195 General and administrative expenses 1,744,699 666,042 2,410,741 2,456,411 526,210 2,982,621 LOSS FROM OPERATIONS (2,166,501 ) (667,887 ) (2,834,388 ) (2,063,216 ) (526,210 ) (2,589,426 ) OTHER INCOME/(EXPENSE) Interest expense (419,264 ) (52,769 ) (472,033 ) (258,522 ) (62,627 ) (321,149 ) Other income/(expense) (118,695 ) - (118,695 ) (402,504 ) (402,504 ) Loss on extinguishment (92,795 ) - (92,795 ) - - - Gain on deconsolidation of subsidiary 4,502,058 - 4,502,058 - - - Total other expense 3,871,304 (52,769 ) 3,818,535 (661,026 ) (62,627 ) (723,653 ) NET LOSS BEFORE INCOME TAXES 1,704,803 (720,656 ) 984,147 (2,724,242 ) (588,837 ) (3,313,079 ) Income tax expense - - - (737,568 ) - (737,568 ) NET INCOME/(LOSS) $ 1,704,803 $ (720,656 ) $ 984,147 $ (3,461,810 ) $ (588,837 ) $ (4,050,647 ) For the Nine Months Ended December 31, 2019 2018 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 2,336,505 $ 569,077 $ 2,905,582 $ 2,728,277 $ - $ 2,728,277 Cost of goods sold (3,157,452 ) (574,544 ) (3,731,996 ) (1,185,878 ) - (1,185,878 ) Gross profit (loss) (820,947 ) (5,467 ) (826,414 ) 1,542,399 - 1,542,399 General and administrative expenses 5,213,561 1,292,613 6,506,174 10,079,767 1,935,766 12,015,533 LOSS FROM OPERATIONS (6,034,508 ) (1,298,080 ) (7,332,588 ) (8,537,368 ) (1,935,766 ) (10,473,134 ) OTHER INCOME/(EXPENSE) Interest expense (1,332,637 ) (178,140 ) (1,510,777 ) (4,681,235 ) (188,947 ) (4,870,182 ) Other income/(expense) 74,920 - 74,920 (3,352,311 ) - (3,352,311 ) Loss on extinguishment (216,954 ) - (216,954 ) - - - Gain on deconsolidation of subsidiary 4,502,058 - 4,502,058 - - - Total other expense 3,027,387 (178,140 ) 2,849,247 (8,033,546 ) (188,947 ) (8,222,493 ) NET LOSS BEFORE INCOME TAXES (3,007,121 ) (1,476,220 ) (4,483,341 ) (16,570,914 ) (2,124,713 ) (18,695,627 ) Income tax expense - - - (737,568 ) - (737,568 ) NET LOSS $ (3,007,121 ) $ (1,476,220 ) $ (4,483,341 ) $ (17,308,482 ) $ (2,124,713 ) $ (19,433,195 )
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the Three Months Ended December 31, 2019 Diluted EPS Computation Income (Numerator) Shares (Denominator) Per-Share Amount Net income from continuing operations available to common stockholders $ 1,704,803 Plus: Income impact of assumed conversions Interest expense on convertible notes payable 51,608 Effect of assumed conversions 51,608 Income from continuing operations plus assumed conversions 1,756,411 Net loss from discontinued operations available to common stockholders (360,329 ) Net income available to common stockholders $ 1,396,082 Weighted-average common shares outstanding 263,055,254 Plus: incremental shares from assumed conversions Warrants 26,648,530 Convertible notes payable 36,086,770 Dilutive potential common shares 62,735,300 Adjusted weighted-average shares 325,790,554 Diluted EPS Net income from continuing operations $ 1,756,411 325,790,554 $ 0.01 Net loss from discontinued operations $ (360,329 ) 325,790,554 $ (0.00 ) Net loss $ 1,396,082 325,790,554 $ 0.00

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	9 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 2019 March 31, 2019 Raw materials $ 299,740 $ 440,414 Work in progress 1,495,301 676,341 Finished goods 257,995 579,604 Allowance to reduce inventory to NRV (492,988 ) (162,567 ) Total inventory $ 1,560,048 $ 1,533,792

Note 4 - Leases (Tables)

Note 4 - Leases (Tables)	9 Months Ended
	Dec. 31, 2019
Notes Tables
Operating and Finance Lease Liabilities, Maturity [Table Text Block]	Year Ending Operating March 31, Finance Leases Leases 2020 (3 months) $ 185,871 $ 17,547 2021 528,443 71,548 2022 544,296 73,939 2023 560,625 38,101 2024 577,444 3,926 Thereafter 4,375,869 - Total undiscounted lease payments 6,772,548 205,061 Less: Amount representing interest (3,072,687 ) (43,925 ) Present value of minimum lease payments 3,699,861 161,136 Less: Current maturities of lease obligations (134,239 ) (47,084 ) Long-term lease obligations $ 3,565,622 $ 114,052

Note 5 - Notes Payable (Tables)

Note 5 - Notes Payable (Tables)	9 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Amounts Recorded in Other Expense [Table Text Block]	Amounts Recorded in Other Expense Related to Royalty Settlement For the Nine Months Ended December 31, 2018 Prepaid royalties expensed during the quarter $ 1,530,000 Promissory note issued to Pacific Leaf, due on or before November 30, 2018 500,000 600,000 shares common stock issued to Pacific Leaf 131,000 Long-term note payable and accrued interest terminated (20,075 ) Total non-cash expense 2,140,925 Cash payments made in August 2018 1,000,000 Total $ 3,140,925
Schedule of Debt [Table Text Block]	As of December 31, 2019 Short-Term Notes Payable Face Value Discount Carrying Value 6% Convertible promissory notes payable (Note 6) $ 1,257,000 $ (257,177 ) $ 999,823 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (584,842 ) 687,021 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,640,000 (142,314 ) 2,497,686 0% Note Payable dated October 23, 2017, current portion 369,444 (23,753 ) 345,691 Line of Credit dated November 27, 2019 330,000 - 330,000 Note Payable to John Davis (Note 9) 151,923 - 151,923 Total Short-Term Notes Payable $ 6,020,230 $ (1,008,086 ) $ 5,012,144

Note 10 - Sale of 50% Members_2

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Tables)	9 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Note Receivable with Imputed Interest [Table Text Block]	Wellcana Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 TOTAL PAYMENTS 8,000,000 DISCOUNT ON NOTE RECEIVABLE (1,389,408 ) NET PRESENT VALUE $ 6,610,592
Schedule of Deconsolidation [Table Text Block]	As of November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 TOTAL 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,899,613 ) Net assets deconsolidated 10,816,185 GAIN ON DECONSOLIDATION $ 4,502,058

Note 1 - Background and Signi_3

Note 1 - Background and Significant Accounting Policies (Details Textual) - USD ($)	Nov. 15, 2019	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019	Nov. 30, 2019	Apr. 01, 2019
Impairment of Long-Lived Assets Held-for-use				$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		158,728,095	108,999,521
Operating Lease, Right-of-Use Asset		$ 144,146
Operating Lease, Liability, Total		$ 161,136
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset						$ 182,624
Operating Lease, Liability, Total						$ 190,173
GB Sciences Louisiana, LLC [Member]
Disposal Group, Including Discontinued Operation, Consideration					$ 8,000,000
Earnout Payments	$ 8,000,000				$ 8,000,000
GB Sciences, Nevada, LLC and GB Sciences Las Vegas, LLC [Member]
Sale of Stock, Percentage of Ownership	75.00%
Sale of Stock, Consideration Received on Transaction	$ 3,000,000
Sale of Stock, Additional Earn-out Payments	$ 3,000,000
GB Sciences, Nevada, LLC and GB Sciences Las Vegas, LLC [Member]
Controlling Interest, Ownership Percentage by Parent		100.00%

Note 1 - Background and Signi_4

Note 1 - Background and Significant Accounting Policies - Discontinued Operations (Details) - USD ($)	Nov. 15, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS		$ 37,300	$ 87,772	$ 37,300	$ 87,772	$ 182,055
Accounts receivable, net of allowance for doubtful accounts of $91,536 and $66,748 at December 31, 2019 and March 31, 2019, respectively		80,436		80,436		488,329
Inventory, net		1,560,048		1,560,048		1,533,792
Prepaid expenses and other current assets		83,240		83,240		262,208
Note receivable		1,365,042		1,365,042
TOTAL CURRENT ASSETS		3,126,066		3,126,066		3,466,771
Property and equipment, net		10,097,430		10,097,430		10,481,706
Intangible assets, net of accumulated amortization of $3,745 at December 31, 2019 and March 31, 2019		2,073,839		2,073,839		1,818,802
Note receivable		5,366,133		5,366,133
Deposits and other noncurrent assets		95,504		95,504		230,651
Operating lease right-of-use assets, net		144,146		144,146
TOTAL ASSETS		20,903,118		20,903,118		30,023,302
Accounts payable		1,998,994		1,998,994		1,374,771
Accrued interest		429,064		429,064		142,112
Accrued liabilities		469,053		469,053		244,931
Notes and convertible notes payable, net of unamortized discount of $1,008,086 and $799,410 at December 31, 2019 and March 31, 2019, respectively		4,860,221		4,860,221		2,229,812
Indebtedness to related parties		324,738		324,738
Income tax payable		506,145		506,145		506,145
Operating lease obligations, current		47,084		47,084
Finance lease obligations, current		134,239		134,239		80,132
TOTAL CURRENT LIABILITIES		8,921,461		8,921,461		6,712,180
Note payable, net of unamortized discount of $0 and $13,929 at December 31, 2019 and March 31, 2019, respectively						161,072
Operating lease obligations, long term		114,052		114,052
Finance lease obligations, long term		3,565,622		3,565,622		3,646,540
TOTAL LIABILITIES		12,601,135		12,601,135		12,867,303
Sales revenue		254,131	695,764	2,336,505	2,728,277
Cost of goods sold		(675,933)	(302,569)	(3,157,452)	(1,185,878)
Gross profit (loss)		(421,802)	393,195	(820,947)	1,542,399
General and administrative expenses		1,744,699	2,456,411	5,213,561	10,079,767
LOSS FROM OPERATIONS		(2,166,501)	(2,063,216)	(6,034,508)	(8,537,368)
Interest expense, net		(419,264)	(258,522)	(1,332,637)	(4,681,235)
Loss on extinguishment		(92,795)		(216,954)
Gain on deconsolidation of subsidiary	$ 4,502,058	4,502,058		4,502,058
Total other expense		3,871,304	(661,026)	3,027,387	(8,033,546)
NET LOSS BEFORE INCOME TAXES		1,704,803	(2,724,242)	(3,007,121)	(16,570,914)
Income tax expense			(737,568)		(737,568)
Net loss		984,147	(4,050,647)	(4,483,341)	(19,433,195)
Continuing Operations [Member]
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS		37,300		37,300		182,055
Accounts receivable, net of allowance for doubtful accounts of $91,536 and $66,748 at December 31, 2019 and March 31, 2019, respectively		80,436		80,436		488,329
Inventory, net		1,560,048		1,560,048		1,533,792
Prepaid expenses and other current assets		83,240		83,240		262,208
Note receivable		1,365,042		1,365,042
TOTAL CURRENT ASSETS		3,126,066		3,126,066		2,466,384
Property and equipment, net		10,097,430		10,097,430		10,481,706
Intangible assets, net of accumulated amortization of $3,745 at December 31, 2019 and March 31, 2019		2,073,839		2,073,839		1,818,802
Note receivable		5,366,133		5,366,133
Deposits and other noncurrent assets		95,504		95,504		230,651
Operating lease right-of-use assets, net		144,146		144,146
TOTAL ASSETS		20,903,118		20,903,118		14,997,543
Accounts payable		1,998,994		1,998,994		1,374,771
Accrued interest		429,064		429,064		142,112
Accrued liabilities		469,053		469,053		244,931
Notes and convertible notes payable, net of unamortized discount of $1,008,086 and $799,410 at December 31, 2019 and March 31, 2019, respectively		4,860,221		4,860,221		2,229,812
Indebtedness to related parties		476,661		476,661
Income tax payable		506,145		506,145		506,145
Operating lease obligations, current		47,084		47,084
Finance lease obligations, current		134,239		134,239		80,132
TOTAL CURRENT LIABILITIES		8,921,461		8,921,461		4,577,903
Note payable, net of unamortized discount of $0 and $13,929 at December 31, 2019 and March 31, 2019, respectively						161,072
Operating lease obligations, long term		114,052		114,052
Finance lease obligations, long term		3,565,622		3,565,622		3,646,540
TOTAL LIABILITIES		12,601,135		12,601,135		8,385,515
Sales revenue		254,131	695,764	2,336,505	2,728,277
Cost of goods sold		(675,933)	(302,569)	(3,157,452)	(1,185,878)
Gross profit (loss)		(421,802)	393,195	(820,947)	1,542,399
General and administrative expenses		1,744,699	2,456,411	5,213,561	10,079,767
LOSS FROM OPERATIONS		(2,166,501)	(2,063,216)	(6,034,508)	(8,537,368)
Interest expense, net		(419,264)	(258,522)	(1,332,637)	(4,681,235)
Other income/(expense)		(118,695)	(402,504)	74,920	(3,352,311)
Loss on extinguishment		(92,795)		(216,954)
Gain on deconsolidation of subsidiary		4,502,058		4,502,058
Total other expense		3,871,304	(661,026)	3,027,387	(8,033,546)
NET LOSS BEFORE INCOME TAXES		1,704,803	(2,724,242)	(3,007,121)	(16,570,914)
Income tax expense			(737,568)		(737,568)
Net loss		1,704,803	(3,461,810)	(3,007,121)	(17,308,482)
Discontinued Operations [Member]
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS						45,703
Accounts receivable, net of allowance for doubtful accounts of $91,536 and $66,748 at December 31, 2019 and March 31, 2019, respectively
Inventory, net						602,714
Prepaid expenses and other current assets						351,970
Note receivable
TOTAL CURRENT ASSETS						1,000,387
Property and equipment, net						13,022,996
Intangible assets, net of accumulated amortization of $3,745 at December 31, 2019 and March 31, 2019
Note receivable
Deposits and other noncurrent assets						1,002,376
Operating lease right-of-use assets, net
TOTAL ASSETS						15,025,759
Accounts payable						1,695,985
Accrued interest
Accrued liabilities						76,415
Notes and convertible notes payable, net of unamortized discount of $1,008,086 and $799,410 at December 31, 2019 and March 31, 2019, respectively						300,000
Indebtedness to related parties
Income tax payable
Operating lease obligations, current
Finance lease obligations, current						61,877
TOTAL CURRENT LIABILITIES						2,134,277
Note payable, net of unamortized discount of $0 and $13,929 at December 31, 2019 and March 31, 2019, respectively
Operating lease obligations, long term
Finance lease obligations, long term						2,347,511
TOTAL LIABILITIES						4,481,788
Sales revenue		192,070		569,077
Cost of goods sold		(193,915)		(574,544)
Gross profit (loss)		(1,845)		(5,467)
General and administrative expenses		666,042	526,210	1,292,613	1,935,766
LOSS FROM OPERATIONS		(667,887)	(526,210)	(1,298,080)	(1,935,766)
Interest expense, net		(52,769)	(62,627)	(178,140)	(188,947)
Other income/(expense)
Loss on extinguishment
Gain on deconsolidation of subsidiary
Total other expense		(52,769)	(62,627)	(178,140)	(188,947)
NET LOSS BEFORE INCOME TAXES		(720,656)	(588,837)	(1,476,220)	(2,124,713)
Income tax expense
Net loss		(720,656)	(588,837)	(1,476,220)	(2,124,713)
Segment, Continuing and Discontinued Operations [Member]
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS		37,300		37,300		227,758
Accounts receivable, net of allowance for doubtful accounts of $91,536 and $66,748 at December 31, 2019 and March 31, 2019, respectively		80,436		80,436		488,329
Inventory, net		1,560,048		1,560,048		2,136,506
Prepaid expenses and other current assets		83,240		83,240		614,178
Note receivable		1,365,042		1,365,042
TOTAL CURRENT ASSETS		3,126,066		3,126,066		3,466,771
Property and equipment, net		10,097,430		10,097,430		23,504,702
Intangible assets, net of accumulated amortization of $3,745 at December 31, 2019 and March 31, 2019		2,073,839		2,073,839		1,818,802
Note receivable		5,366,133		5,366,133
Deposits and other noncurrent assets		95,504		95,504		1,233,027
Operating lease right-of-use assets, net		144,146		144,146
TOTAL ASSETS		20,903,118		20,903,118		30,023,302
Accounts payable		1,998,994		1,998,994		3,070,756
Accrued interest		429,064		429,064		142,112
Accrued liabilities		469,053		469,053		321,346
Notes and convertible notes payable, net of unamortized discount of $1,008,086 and $799,410 at December 31, 2019 and March 31, 2019, respectively		4,860,221		4,860,221		2,529,812
Indebtedness to related parties		476,661		476,661
Income tax payable		506,145		506,145		506,145
Operating lease obligations, current		47,084		47,084
Finance lease obligations, current		134,239		134,239		142,009
TOTAL CURRENT LIABILITIES		8,921,461		8,921,461		6,712,180
Note payable, net of unamortized discount of $0 and $13,929 at December 31, 2019 and March 31, 2019, respectively						161,072
Operating lease obligations, long term		114,052		114,052
Finance lease obligations, long term		3,565,622		3,565,622		5,994,051
TOTAL LIABILITIES		12,601,135		12,601,135		$ 12,867,303
Sales revenue		446,201	695,764	2,905,582	2,728,277
Cost of goods sold		(869,848)	(302,569)	(3,731,996)	(1,185,878)
Gross profit (loss)		(423,647)	393,195	(826,414)	1,542,399
General and administrative expenses		2,410,741	2,982,621	6,506,174	12,015,533
LOSS FROM OPERATIONS		(2,834,388)	(2,589,426)	(7,332,588)	(10,473,134)
Interest expense, net		(472,033)	(321,149)	(1,510,777)	(4,870,182)
Other income/(expense)		(118,695)	(402,504)	74,920	(3,352,311)
Loss on extinguishment		(92,795)		(216,954)
Gain on deconsolidation of subsidiary		4,502,058		4,502,058
Total other expense		3,818,535	(723,653)	2,849,247	(8,222,493)
NET LOSS BEFORE INCOME TAXES		984,147	(3,313,079)	(4,483,341)	(18,695,627)
Income tax expense			(737,568)		(737,568)
Net loss		$ 984,147	$ (4,050,647)	$ (4,483,341)	$ (19,433,195)

Note 1 - Background and Signi_5

Note 1 - Background and Significant Accounting Policies - Earnings (Loss) Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Net income from continuing operations available to common stockholders	$ 1,704,803	$ (3,461,810)	$ (3,007,121)	$ (17,308,482)
Interest expense on convertible notes payable	51,608
Effect of assumed conversions	51,608
Income from continuing operations plus assumed conversions	1,756,411	(3,461,810)	(3,007,121)	(17,308,482)
Net loss from discontinued operations available to common stockholders	(360,329)	(301,431)	(738,113)	(1,361,747)
Net income available to common stockholders	$ 1,396,082	$ (3,763,241)	$ (3,745,234)	$ (18,670,229)
Weighted-average common shares outstanding (in shares)	263,055,254	222,856,453	253,297,660	200,971,724
Warrants (in shares)	26,648,530
Convertible notes payable (in shares)	36,086,770
Dilutive potential common shares (in shares)	62,735,300
Adjusted weighted-average shares (in shares)	325,790,554	222,856,453	253,297,660	200,971,724
Net income from continuing operations per common share diluted (in dollars per share)	$ 0.01	$ (0.02)	$ (0.01)	$ (0.08)
Net loss from discontinued operations per common share diluted (in dollars per share)				(0.01)
Net loss per common share diluted (in dollars per share)		$ (0.02)	$ (0.01)	$ (0.09)

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Retained Earnings (Accumulated Deficit), Ending Balance	$ (88,764,145)		$ (84,743,836)
Working Capital Deficit	5,795,395		3,245,409
Net Cash Provided by (Used in) Operating Activities, Total	(4,248,291)	$ (7,847,751)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	$ (1,244,721)	$ (447,852)
Discontinued Operations [Member]
Working Capital Deficit			$ 1,133,890

Note 3 - Inventory - Schedule o

Note 3 - Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Raw materials	$ 299,740	$ 440,414
Work in progress	1,495,301	676,341
Finished goods	257,995	579,604
Allowance to reduce inventory to NRV	(492,988)	(162,567)
Total inventory	$ 1,560,048	$ 1,533,792

Note 4 - Leases (Details Textua

Note 4 - Leases (Details Textual) - USD ($)	9 Months Ended
	Dec. 31, 2019	Apr. 01, 2019	Mar. 31, 2019
Operating Lease, Right-of-Use Asset	$ 144,146
Operating Lease, Liability, Total	$ 161,136
Lessee, Operating Lease, Discount Rate	17.00%
Finance Lease Costs	$ 790,666
Finance Lease, Interest Expense	474,686
Finance Lease, Right-of-Use Asset, Amortization	315,980
Operating Lease, Cost	61,144
Operating Lease, Interest Expense	22,667
Operating Lease, Right-of-Use Asset Amortization	38,477
Discontinued Operations [Member]
Operating Lease, Right-of-Use Asset
Finance Lease Costs	280,227
Finance Lease, Interest Expense	153,977
Finance Lease, Right-of-Use Asset, Amortization	$ 126,250
Minimum [Member]
Lessee, Finance Lease, Discount Rate	10.20%
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset		$ 182,624
Operating Lease, Liability, Total		$ 190,173

Note 4 - Leases - Future Minimu

Note 4 - Leases - Future Minimum Lease Payments (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
2020 (6 Months), finance leases	$ 185,871
2020 (6 Months), operating leases	17,547
2021, finance leases	528,443
2021, operating leases	71,548
2022, finance leases	544,296
2022, operating leases	73,939
2023, finance leases	560,625
2023, operating leases	38,101
2024, finance lease	577,444
2024, operating leases	3,926
Thereafter, finance leases	4,375,869
Thereafter, operating leases
Total undiscounted lease payments, finance leases	6,772,548
Total undiscounted lease payments, operating leases	205,061
Less: Amount representing interest, finance leases	(3,072,687)
Less: Amount representing interest, operating leases	(43,925)
Present value of minimum lease payments, finance leases	3,699,861
Present value of minimum lease payments, operating leases	161,136
Less: Current maturities of lease obligations, finance leases	(134,239)	$ (80,132)
Less: Current maturities of lease obligations, operating leases	(47,084)
Finance lease obligations, long term	3,565,622	3,646,540
Operating lease obligations, long term	$ 114,052

Note 5 - Notes Payable (Details

Note 5 - Notes Payable (Details Textual)

Nov. 15, 2019USD ($)

Mar. 04, 2019USD ($)

Feb. 06, 2019USD ($)

Jan. 16, 2019USD ($)

Dec. 21, 2018USD ($)shares

Dec. 20, 2018USD ($)

Jul. 31, 2018USD ($)shares

Jul. 28, 2018USD ($)

Oct. 23, 2017USD ($)

Feb. 18, 2020USD ($)

Feb. 14, 2020USD ($)

Dec. 31, 2018USD ($)

Sep. 30, 2018USD ($)

Sep. 30, 2018USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2018USD ($)shares

Feb. 18, 2020USD ($)

Nov. 15, 2019USD ($)

Mar. 31, 2019USD ($)

Nov. 27, 2019USD ($)

Nov. 30, 2018

Stock Issued to Settle Royalty Agreement, Value

$ 95,000

$ 131,000

Interest Paid, Excluding Capitalized Interest, Operating Activities

451,040

539,242

Other Expenses, Total

3,140,925

Proceeds from Lines of Credit, Total

330,000

Long-term Line of Credit, Total

330,000

Subsequent Event [Member]

Proceeds from Lines of Credit, Total

$ 150,000

$ 480,000

Line of Credit Facility, Maximum Borrowing Capacity, Increased

$ 10,000

GB Sciences, Nevada, LLC and GB Sciences Las Vegas, LLC [Member]

Noncontrolling Interest, Ownership Percentage to be Sold by Parent

75.00%

75.00%

75.00%

Line of Credit [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 470,000

Promissory Note [Member]

Debt Instrument, Face Amount

6,020,230

Other Expense [Member]

Repayments of Debt

$ 1,000,000

Stock Issued to Settle Royalty Agreement, Shares | shares

600,000

Stock Issued During Period, Expense, New Issues

$ 131,000

Royalty Expense

1,530,000

$ 1,530,000

The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]

Debt Instrument, Face Amount

369,444

Debt Instrument, Debt Default, Remaining Balance

369,444

The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]

Debt Instrument, Face Amount

$ 700,000

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Interest Expense, Debt, Total

31,092

Debt Instrument, Term

3 years

Debt Instrument, Present Value

$ 521,067

Receivable with Imputed Interest, Effective Yield (Interest Rate)

20.30%

Debt Instrument, Unamortized Discount, Total

$ 178,933

Debt Instrument, Accrued Monthly Payments, Amount

$ 155,555

Days to Cure Breach of Default After Notification From Lender

10

Debt Instrument, Debt Default, Interest Rate Penalty

10.00%

Amendment and Termination Agreement [Member] | Pacific Leaf [Member]

Stock Issued to Settle Royalty Agreement, Shares | shares

100,000

Stock Issued to Settle Royalty Agreement, Value

$ 36,000

Amendment and Termination Agreement [Member] | Pacific Leaf [Member] | Other Expense [Member]

Stock Issued to Settle Royalty Agreement, Value

$ 36,000

Nevada Medical Marijuana Production License Agreement [Member]

Payments to Acquire License

$ 500,000

Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]

Ownership of Licence

100.00%

Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]

Ownership of Licence

100.00%

Pacific Leaf [Member] | The 6% Note Payable Due November 30, 2018 [Member]

Debt Conversion, Original Debt, Amount

$ 500,000

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Interest Expense, Debt, Total

$ 5,425

Stock Issued to Settle Royalty Agreement, Shares | shares

500,000

Repayments of Notes Payable

$ 210,000

$ 100,000

$ 100,000

$ 100,000

Interest Paid, Excluding Capitalized Interest, Operating Activities

12,164

Repayments of Notes Payable, Principal

$ 87,836

Stock Issued During Period, Expense, New Issues

$ 95,000

Pacific Leaf [Member] | Amendment and Termination Agreement [Member]

Repayments of Debt

1,000,000

Debt Instrument, Face Amount

$ 1,500,000

Pacific Leaf [Member] | Amendment and Termination Agreement [Member] | Other Expense [Member]

Repayments of Debt

$ 1,000,000

$ 1,000,000

BCM MED [Member] | The 0% Note Payable Dated December 20, 2018 [Member] | Notes Payable, Other Payables [Member]

Repayments of Debt

$ 266,667

Debt Instrument, Face Amount

$ 300,000

Debt Instrument, Periodic Payments, Number of Monthly Payments

8

Debt Instrument, Periodic Payment, Total

$ 33,333

Debt Instrument, Increase (Decrease), Net, Total

$ 33,333

Note 5 - Notes Payable - Amount

Note 5 - Notes Payable - Amounts Recorded in Other Expense (Details) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2018
Total		$ 3,140,925
Other Expense [Member]
Prepaid royalties expensed during the quarter	$ 1,530,000	1,530,000
Promissory note issued to Pacific Leaf, due on or before November 30, 2018		500,000
600,000 shares common stock issued to Pacific Leaf		131,000
Long-term note payable and accrued interest terminated		(20,075)
Total non-cash expense		2,140,925
Cash payments made in August 2018		$ 1,000,000

Note 5 - Notes Payable - Amou_2

Note 5 - Notes Payable - Amounts Recorded in Other Expense (Details) (Parentheticals)	9 Months Ended
	Dec. 31, 2018shares
Other Expense [Member]
Shares common stock issued to Pacific Leaf (in shares)	600,000

Note 5 - Notes Payable - Schedu

Note 5 - Notes Payable - Schedule of Debt Payable (Details) - USD ($)	Dec. 31, 2019	Apr. 23, 2019	Mar. 31, 2019
Discount, short-term notes payable	$ (1,008,086)		$ (799,410)
Note Payable to John Davis [Member]
Face Value, short-term notes payable	151,923
Discount, short-term notes payable
Carrying Value, short-term notes payable	151,923
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Face Value, short-term notes payable	1,257,000
Discount, short-term notes payable	(257,177)
Carrying Value, short-term notes payable	999,823
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Face Value, short-term notes payable	2,640,000	$ 2,765,000
Discount, short-term notes payable	(142,314)
Carrying Value, short-term notes payable	2,497,686
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Face Value, short-term notes payable	1,271,863
Discount, short-term notes payable	(584,842)
Carrying Value, short-term notes payable	687,021
Promissory Note [Member]
Face Value, short-term notes payable	6,020,230
Discount, short-term notes payable	(1,008,086)
Carrying Value, short-term notes payable	5,012,144
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable	369,444
Discount, short-term notes payable	(23,753)
Carrying Value, short-term notes payable	345,691
Line of Credit [Member]
Face Value, short-term notes payable	330,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	$ 330,000

Note 6 - Convertible Notes (Det

Note 6 - Convertible Notes (Details Textual)	Dec. 16, 2019USD ($)$ / sharesshares	Nov. 27, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / sharesshares	Oct. 30, 2019USD ($)$ / sharesshares	Oct. 23, 2019USD ($)$ / shares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 12, 2019USD ($)$ / shares	May 28, 2019USD ($)$ / sharesshares	Apr. 23, 2019USD ($)$ / shares	Feb. 28, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Nov. 15, 2019	Mar. 31, 2019USD ($)
Interest Payable, Current														$ 429,064					$ 429,064			$ 142,112
Amortization of Debt Discount (Premium)																			$ 741,912	$ 685,766
Debt Conversion, Converted Instrument, Shares Issued | shares																			7,583,333
Gain (Loss) on Extinguishment of Debt, Total														(92,795)					$ (216,954)
Interest Expense, Debt, Excluding Amortization																			93,931	3,464,187
Induced Conversion of Convertible Debt Expense														127,059					127,059
GB Sciences, Nevada, LLC and GB Sciences Las Vegas, LLC [Member]
Noncontrolling Interest, Ownership Percentage to be Sold by Parent		75.00%																			75.00%
Warrants Issued in March 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Issued | shares													3,862,000					4,138,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares													1					1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 0.60					$ 0.60
Warrants and Rights Outstanding, Term													3 years					3 years
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Issued | shares																16,464,000	12,340,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares																1	1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares												$ 0.65				$ 0.65	$ 0.65
Warrants and Rights Outstanding, Term																3 years	3 years
Debt Instrument, Convertible, Number of Warrants												4,000
Convertible Notes Payable [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature																			829,736
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount													$ 965,500					$ 1,034,500
Debt Instrument, Term													3 years					3 years
Debt Instrument, Convertible, Beneficial Conversion Feature													$ 416,733					$ 487,957
Debt Instrument, Convertible, Discount, Fair Value of Warrants													$ 548,767					$ 480,236
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments													3,862,000					4,138,000
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount																$ 4,116,000	$ 3,085,000
Debt Instrument, Term												3 years				3 years	3 years
Debt Instrument, Convertible, Beneficial Conversion Feature																$ 1,600,808	$ 1,541,797
Debt Instrument, Convertible, Discount, Fair Value of Warrants																$ 2,417,856	$ 1,532,335
Debt Instrument, Face Amount Per Note												$ 1,000
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments												4,000				16,464,000	12,340,000
Debt Instrument, Convertible, Conversion Price | $ / shares												$ 0.25
Convertible Notes Payable [Member] | March 2017 and July 2017 Note Offerings [Member]
Long-term Debt, Gross														999,823					999,823
Debt Instrument, Unamortized Discount, Total														257,177					257,177
Interest Payable, Current														178,381					178,381
Interest Expense, Debt, Total																			364,575
Amortization of Debt Discount (Premium)																			307,752
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Face Amount									$ 2,765,000					2,640,000					2,640,000
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 0.0375	$ 0.06					$ 0.17		$ 0.0375
Debt Instrument, Unamortized Discount, Total									$ 265,000
Interest Expense, Debt, Total																			164,150
Amortization of Debt Discount (Premium)																			109,870
Debt Conversion, Original Debt, Amount			$ 50,000	$ 75,000							$ 125,000
Debt Conversion, Converted Instrument, Shares Issued | shares			1,333,333	1,250,000
Short-term Debt, Total														$ 2,497,686					$ 2,497,686
Debt Instrument, Debt Default, Interest Rate Penalty														15.00%					15.00%
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total									440,000
Payments for Brokerage Fees									$ 175,000
Debt Instrument, Debt Default, Increase in Balance Outstanding, Percentage														10.00%					10.00%
Induced Conversion of Convertible Debt Expense			$ 62,353	$ 64,706										$ 127,059					$ 127,059
Promissory Note [Member]
Debt Instrument, Face Amount														6,020,230					6,020,230
Short-term Debt, Total														5,012,144					5,012,144
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage												6.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Face Amount										$ 1,500,000
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 92,796		$ 133,806			$ 176,471
Debt Instrument, Interest Rate, Stated Percentage							8.00%	8.00%		8.00%
Debt Instrument, Unamortized Discount, Total	$ 57,551					$ 9,579		$ 17,225						584,842					584,842
Interest Payable, Current														32,186					32,186
Interest Expense, Debt, Total																			61,286
Debt Conversion, Original Debt, Amount	120,000					110,000		170,000
Debt Instrument, Increase (Decrease), Net, Total	(62,449)	$ 30,000				(100,421)	$ 100,000	(152,775)
Short-term Debt, Total	$ 1,271,863	1,361,863			1,269,067	$ 1,361,863	1,338,057	$ 1,330,000						$ 687,021					$ 687,021
Proceeds from Related Party Debt							100,000
Debt Instrument, Increase, Accrued Interest							41,863
Gain (Loss) on Extinguishment of Debt, Total		$ 0			$ (92,796)		$ (124,158)
Debt Instrument, Debt Default, Interest Rate Penalty														10.00%					10.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Minimum [Member]
Days to Cure Breach of Default After Notification From Lender														5					5
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Maximum [Member]
Days to Cure Breach of Default After Notification From Lender														10					10
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent										100.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments										8,823,529
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.04	$ 0.04			$ 0.08	$ 0.11	$ 0.11	$ 0.17		$ 0.17
Debt Conversion, Converted Instrument, Shares Issued | shares	3,000,000					1,000,000		1,000,000
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Face Amount														$ 1,271,863					$ 1,271,863
Interest Expense, Debt, Total																			89,624
Amortization of Debt Discount (Premium)																			62,354
Short-term Debt, Total														$ 687,021					687,021
Interest Expense, Debt, Excluding Amortization																			$ 27,270

Note 7 - Capital Transactions (

Note 7 - Capital Transactions (Details Textual) - USD ($)	Dec. 31, 2019	Dec. 16, 2019	Nov. 27, 2019	Nov. 18, 2019	Oct. 30, 2019	Oct. 10, 2019	Oct. 01, 2019	Aug. 01, 2019	Jul. 12, 2019	May 28, 2019	Dec. 31, 2019	Nov. 18, 2019	Dec. 31, 2019	Jul. 11, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Oct. 23, 2019	Aug. 15, 2019	Jul. 10, 2019	Apr. 23, 2019	Mar. 31, 2019	Feb. 28, 2019	Jan. 15, 2019	Dec. 04, 2018	Apr. 08, 2018	Apr. 07, 2018
Common Stock, Shares Authorized	600,000,000										600,000,000		600,000,000			600,000,000			600,000,000			600,000,000				400,000,000	250,000,000
Debt Conversion, Converted Instrument, Shares Issued																7,583,333
Induced Conversion of Convertible Debt Expense													$ 127,059			$ 127,059
Exercise of Warrants for Stock, Shares																12,574,750
Stock Issued During Period, Shares, Issued for Services							2,000,000									2,500,000
Consulting Service Expense																$ 214,000
Stock Issued During Period, Shares, New Issues																7,668,167
Proceeds from Issuance of Common Stock and Warrants						$ 240,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 15,131										$ 15,131		$ 15,131			$ 15,131
Employees and Consultants [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense																$ 241,242
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	10,383,334										10,383,334		10,383,334			10,383,334
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	2,383,000										2,383,000		2,383,000			2,383,000
Private Placement [Member]
Brokerage Fees for Issuance of Common Stock and Warrants																$ 71,529
Units of Common Stock and Warrants, Authorized																								20,000,000	15,000,000
Units of Combined Common Stock and Warrants, Price Per Unit																								$ 0.15	$ 0.20
Units of Combined Common Stock and Warrants, Value																									$ 3,000,000
Proceeds from Issuance of Private Placement																$ 478,696
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Outstanding														70,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.04										$ 0.04		$ 0.04			$ 0.04
Class of Warrant or Right, Temporarily Reduced Exercise Price of Warrants or Rights														$ 0.10
Class of Warrant or Right, Exercises in Period									9,449,750		3,125,000
Proceeds from Warrant Exercises									$ 850,478		$ 112,500
Brokerage Fees for Issuance of Common Stock and Warrants									94,498		12,500
Inducement Dividend, Exercise of Warrants	$ 37,499								$ 230,025		$ 37,499		$ 37,499			$ 37,499
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 0.65
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights																				$ 0.30
Warrants Issued In the Private Placement on December 4, 2018 [Member] | Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.30										$ 0.30		$ 0.30			$ 0.30								$ 0.30	$ 0.60
Units of Combined Common Stock and Warrants, Warrants Per Unit																									1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																									1
Warrants and Rights Outstanding, Term																									5 years
Class of Warrant or Right, Issued																3,668,167
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1										1		1			1
Warrants Issued to an Investor on October 10, 2019 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.08
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1
Warrants and Rights Outstanding, Term						3 years
Class of Warrant or Right, Issued						2,000,000
Warrants and Rights Outstanding						$ 110,000
Warrants Issued to Broker Participating in Private Placement on December 4, 2018 [Member]
Class of Warrant or Right, Outstanding	87,526,411										87,526,411		87,526,411			87,526,411
Warrants Issued to Broker Participating in Private Placement on December 4, 2018 [Member] | Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.30										$ 0.30		$ 0.30			$ 0.30
Class of Warrant or Right, Issued	1,954,613
Class of Warrant or Right, Expense	$ 132,914
Warrants Issued to Broker Participating in Private Placement on December 4, 2018 [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1										1		1			1
Warrants Issued to Broker Participating in Private Placement on December 4, 2018 [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.30										$ 0.30		$ 0.30			$ 0.30
Common Stock [Member]
Exercise of Warrants for Stock, Shares													3,125,000			12,574,750	12,657,875
Stock Issued During Period, Shares, Issued for Services													2,500,000		2,341,568	2,500,000	3,885,412
Stock Issued During Period, Shares, New Issues						4,000,000							4,000,000		3,470,000	7,668,167	23,747,778
Cancellation of Shares Issued for Services																400,000
Common Stock [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues																3,668,167
Units of Combined Common Stock and Warrants, Shares Per Unit																									1
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Conversion, Original Debt, Amount		$ 120,000						$ 110,000		$ 170,000
Debt Instrument, Interest Rate, Stated Percentage									8.00%	8.00%													8.00%
Debt Instrument, Unamortized Discount, Total	$ 584,842	57,551						9,579		$ 17,225	$ 584,842		$ 584,842			$ 584,842
Debt Instrument, Increase (Decrease), Net, Total		(62,449)	$ 30,000					(100,421)	$ 100,000	(152,775)
Short-term Debt, Total	687,021	$ 1,271,863	$ 1,361,863					$ 1,361,863	$ 1,338,057	$ 1,330,000	687,021		687,021			687,021		$ 1,269,067
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued		3,000,000						1,000,000		1,000,000
Debt Instrument, Convertible, Conversion Price		$ 0.04	$ 0.04					$ 0.11	$ 0.11	$ 0.17								$ 0.08					$ 0.17
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Conversion, Converted Instrument, Shares Issued				1,333,333	1,250,000
Debt Conversion, Original Debt, Amount				$ 50,000	$ 75,000							$ 125,000
Debt Instrument, Interest Rate, Stated Percentage																					8.00%
Debt Instrument, Convertible, Conversion Price				$ 0.0375	$ 0.06							$ 0.0375									$ 0.17
Debt Instrument, Unamortized Discount, Total																					$ 265,000
Short-term Debt, Total	$ 2,497,686										$ 2,497,686		2,497,686			2,497,686
Induced Conversion of Convertible Debt Expense				$ 62,353	$ 64,706								$ 127,059			$ 127,059

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual)	Oct. 01, 2019USD ($)shares	Jun. 06, 2019USD ($)shares	Dec. 06, 2018USD ($)$ / sharesshares	Sep. 18, 2017USD ($)	Dec. 31, 2019USD ($)	Jun. 06, 2019shares	Dec. 31, 2019USD ($)shares	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Monthly Consulting Fee	$ 50,000
Stock Issued During Period, Shares, Issued for Services | shares	2,000,000						2,500,000
Quarterly Stock Fee, Shares | shares	2,000,000
Consulting Expense Related to Common Stock Payments					$ 180,000
Consulting Expense Related to Cash Payments					$ 50,000
Asset Forfeiture, Charge								$ 200,000
SylvaCap Media [Member]
Monthly Consulting Fee			$ 10,000
Monthly Consulting Fee, Number of Months			12
SylvaCap Media [Member] | Restricted Stock [Member]
Stock Issued During Period, Shares, Issued for Services | shares		2,000,000	2,000,000			4,000,000
Loss on Contract Termination		$ 135,000
Shares Unissued for Services, Contract Termination | shares		2,000,000
Warrants Issued to SylvaCap Media for Business Advisory and Consulting Services [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 0.1125
Warrants and Rights Outstanding			$ 244,000
Class of Warrant or Right, Expense							$ 162,667
Agreement With Louisiana State Unversity AgCenter [Member]
Term of Agreement				5 years			3 years
Option to Renew Agreement, Amount				2
Term of Agreement, Renewal				5 years
Research and Development Expense, Total				$ 500,000			$ 250,000		$ 750,000

Note 9 - Related Party Transa_2

Note 9 - Related Party Transactions (Details Textual) - USD ($)	Oct. 01, 2019	Nov. 01, 2017	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Due to Officers or Stockholders, Current				$ 324,738
Notes Payable, Related Parties, Current				$ 151,923
Stock Issued During Period, Shares, Issued for Services	2,000,000			2,500,000
Other Expenses, Total					$ 3,140,925
THC Note [Member] | Line of Credit [Member]
Line of Credit Facility, Current Borrowing Capacity		$ 300,000
Repayment as Percent of Gross Revenue		25.00%
Proceeds from Related Party Debt					253,034
Officer [Member]
Due to Officers or Stockholders, Current				$ 324,738
Unpaid Wages, Related Parties				142,637
Unpaid Bonuses, Related Parties				75,747
Reimbursement for Business Expense, Related Parties				106,354
John Davis [Member]
Notes Payable, Related Parties, Current				$ 151,923
Quantum Shop [Member]
Related Party Transaction, Amounts of Transaction					1,100,000
Electrum Partners, LLC [Member]
Related Party Transaction, Amounts of Transaction					$ 73,904
Stock Issued During Period, Shares, Issued for Services					285,412
Restricted Stock or Unit Expense					$ 99,596
THCLLC [Member]
Capitalization of Fair Value of Machinery and Equipment			$ 139,411
Other Expenses, Total			$ 113,623		$ 113,623
THCLLC [Member] | Minimum [Member]
Royalty Rates		20.00%
THCLLC [Member] | Maximum [Member]
Royalty Rates		25.00%

Note 10 - Sale of 50% Members_3

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) - USD ($)	Nov. 15, 2019	Feb. 12, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Nov. 30, 2019
Deconsolidation, Gain (Loss), Amount	$ 4,502,058		$ 4,502,058		$ 4,502,058
Wellcana Note [Member]
Note Receivable, Interest Rate	5.00%
Receivable with Imputed Interest, Discount	$ 1,389,408
Receivable with Imputed Interest, Effective Yield (Interest Rate)	17.00%
Receivable with Imputed Interest, Net Amount, Total	$ 6,610,592
GB Sciences Louisiana, LLC [Member]
Proceeds from Divestiture of Businesses	8,000,000
Earnout Payments	$ 8,000,000							$ 8,000,000
Wellcana Group, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		49.99%
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership	50.01%	15.00%
Sale of Stock, Consideration Received on Transaction		$ 3,000,000					$ 7,000,000
Sale of Stock, Percentage of Ownership Available For Sale		35.00%
Sale of Stock, Percentage of Available Stock For Sale, Percent to be Sold Per Transaction		5.00%
Sale of Stock, Consideration Received Per Transaction		$ 1,000,000

Note 10 - Sale of 50% Members_4

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Note Receivable (Details) - Wellcana Note [Member]	Nov. 15, 2019USD ($)
June 1, 2020	$ 500,000
September 1, 2020	750,000
December 1, 2020	1,000,000
March 1, 2020	1,250,000
June 1, 2021	1,500,000
September 1, 2021	1,500,000
December 1, 2021	1,500,000
TOTAL PAYMENTS	8,000,000
DISCOUNT ON NOTE RECEIVABLE	(1,389,408)
NET PRESENT VALUE	$ 6,610,592

Note 10 - Sale of 50% Members_5

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Deconsolidation (Details) - USD ($)	Nov. 15, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
GAIN ON DECONSOLIDATION	$ 4,502,058	$ 4,502,058		$ 4,502,058
GB Sciences Louisiana, LLC [Member]
Present value of promissory note	6,610,592
Carrying amount of non-controlling interest	8,707,651
TOTAL	15,318,243
Carrying amount of assets	14,715,798
Carrying amount of liabilities	(3,899,613)
Net assets deconsolidated	10,816,185
GAIN ON DECONSOLIDATION	$ 4,502,058

Note 11 - Sale of Membership _2

Note 11 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) - USD ($)	Dec. 06, 2019	Nov. 27, 2019
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 470,000
Teco Note [Member] | Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 470,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
AJE Management, LLC [Member]
Management Fee	$ 75,000
Teco [Member]
Sale of Stock, Percentage of Ownership		75.00%
Sale of Stock, Consideration Received on Transaction		$ 3,000,000
Sale of Stock, Additional Earn-out Payments		$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership		100.00%
Sale of Stock, Consideration Received on Transaction		$ 300,000

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member]	2 Months Ended
	Feb. 18, 2020USD ($)$ / sharesshares
Class of Warrant or Right, Exercises in Period | shares	2,214,000
Class of Warrant or Right, Exercises in Period, Exercise Price | $ / shares	$ 0.04
Proceeds from Warrant Exercises	$ 79,704
Brokerage Fees	$ 8,856